An  	An  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibody  	antibody  	 NN	B-NP
induction  	induction  	 NN	I-NP
during  	during  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
new  	new  	 JJ	O
US  	US  	 NNP	O
formulation  	formulation  	 NN	B-NP
of  	of  	 IN	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
The  	The  	 DT	O
induction  	induction  	 NN	B-NP
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
during  	during  	 IN	O
the  	the  	 DT	O
aesthetic  	aesthetic  	 JJ	B-NP
application  	application  	 NN	I-NP
of  	of  	 IN	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
is  	is  	 VBZ	O
rare 	rare 	 JJ	O
,  	,  	 ,	O
but  	but  	 CC	O
of  	of  	 IN	O
potential  	potential  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
concern 	concern 	 NN	I-NP
.  	.  	 .	O
Phase  	Phase  	 NNP	O
III  	III  	 NNP	O
studies  	studies  	 NNS	O
of  	of  	 IN	O
a  	a  	 DT	O
new  	new  	 JJ	O
US  	US  	 NNP	O
formulation  	formulation  	 NN	B-NP
of  	of  	 IN	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A 	A 	 NN	O
,  	,  	 ,	O
Dysport  	Dysport  	 NNP	B-NP
( 	( 	 -LRB-	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
[ 	[ 	 -LRB-	O
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	B-NP
] 	] 	 -RRB-	O
;  	;  	 :	O
Medicis  	Medicis  	 NNP	B-NP
Aesthetics 	Aesthetics 	 NNP	I-NP
,  	,  	 ,	O
Scottsdale 	Scottsdale 	 NNP	B-NP
,  	,  	 ,	O
AZ 	AZ 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
have  	have  	 VBP	O
not  	not  	 RB	O
identified  	identified  	 VBN	O
any  	any  	 DT	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibody  	antibody  	 NN	B-NP
formation  	formation  	 NN	I-NP
during  	during  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
received  	received  	 VBD	O
up  	up  	 RP	O
to  	to  	 TO	O
nine  	nine  	 CD	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
To  	To  	 TO	O
provide  	provide  	 VB	O
an  	an  	 DT	O
in-depth  	in-depth  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
potential  	potential  	 NN	O
for  	for  	 IN	O
induction  	induction  	 NN	B-NP
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	B-NP
population  	population  	 NN	I-NP
enrolled  	enrolled  	 NN	I-NP
in  	in  	 IN	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trials  	trials  	 NNS	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
First  	First  	 NNP	O
and  	and  	 CC	O
last  	last  	 JJ	O
available  	available  	 JJ	O
serum  	serum  	 JJ	O
samples  	samples  	 NNS	O
from  	from  	 IN	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
Glabellar  	Glabellar  	 NNP	I-NP
Lines  	Lines  	 NNPS	I-NP
Development  	Development  	 NNP	I-NP
Program  	Program  	 NNP	I-NP
were  	were  	 VBD	O
screened  	screened  	 VBN	O
for  	for  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
radioimmunoprecipitation  	radioimmunoprecipitation  	 JJ	B-NP
assay  	assay  	 NNS	I-NP
( 	( 	 -LRB-	O
RIPA 	RIPA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
confirmatory  	confirmatory  	 JJ	B-NP
competitive  	competitive  	 JJ	I-NP
assay  	assay  	 NNS	I-NP
( 	( 	 -LRB-	O
RIPA-C 	RIPA-C 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Confirmed  	Confirmed  	 VBN	B-NP
RIPA-C-positive  	RIPA-C-positive  	 JJ	I-NP
samples  	samples  	 NNS	I-NP
were  	were  	 VBD	O
further  	further  	 RB	O
evaluated  	evaluated  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
using  	using  	 VBG	O
a  	a  	 DT	O
mouse  	mouse  	 NN	B-NP
protection  	protection  	 NN	I-NP
assay  	assay  	 NNS	I-NP
( 	( 	 -LRB-	O
MPA 	MPA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
a  	a  	 DT	O
highly  	highly  	 RB	O
specific  	specific  	 JJ	O
bioassay  	bioassay  	 NN	B-NP
for  	for  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies 	antibodies 	 NNS	B-NP
.  	.  	 .	O
We  	We  	 PRP	O
conducted  	conducted  	 VBD	O
safety  	safety  	 NN	O
and  	and  	 CC	O
efficacy  	efficacy  	 JJ	B-NP
evaluations 	evaluations 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
day  	day  	 NN	I-NP
30  	30  	 CD	O
responder  	responder  	 JJ	B-NP
rate  	rate  	 NN	I-NP
( 	( 	 -LRB-	O
a  	a  	 DT	O
rating  	rating  	 NN	O
of  	of  	 IN	O
no  	no  	 DT	O
or  	or  	 CC	O
mild  	mild  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
duration  	duration  	 NN	O
of  	of  	 IN	O
response  	response  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
treatment  	treatment  	 NN	B-NP
cycle 	cycle 	 NN	I-NP
.  	.  	 .	O
Of  	Of  	 IN	O
1554  	1554  	 CD	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
received  	received  	 VBD	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
( 	( 	 -LRB-	O
10  	10  	 CD	O
units  	units  	 NNS	O
at  	at  	 IN	O
five  	five  	 CD	O
injection  	injection  	 NN	B-NP
points 	points 	 NNS	I-NP
,  	,  	 ,	O
for  	for  	 IN	O
a  	a  	 DT	O
total  	total  	 JJ	B-NP
dose  	dose  	 NN	I-NP
of  	of  	 IN	O
50  	50  	 CD	O
units 	units 	 NNS	B-NP
/ 	/ 	 JJ	I-NP
treatment 	treatment 	 NN	I-NP
;  	;  	 :	O
range  	range  	 NN	O
one  	one  	 CD	O
to  	to  	 TO	O
nine  	nine  	 CD	O
treatments 	treatments 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
five  	five  	 CD	O
( 	( 	 -LRB-	O
0.32 	0.32 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
antibody  	antibody  	 JJ	B-NP
positive  	positive  	 JJ	O
on  	on  	 IN	O
the  	the  	 DT	O
RIPA-C  	RIPA-C  	 JJ	B-NP
assay-two  	assay-two  	 NN	O
at  	at  	 IN	O
baseline  	baseline  	 NN	B-NP
and  	and  	 CC	O
three  	three  	 CD	O
at  	at  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
treatment  	treatment  	 NN	B-NP
cycle 	cycle 	 NN	I-NP
.  	.  	 .	O
None  	None  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
RIPA-C-positive  	RIPA-C-positive  	 JJ	B-NP
samples  	samples  	 NNS	I-NP
tested  	tested  	 VBD	O
positive  	positive  	 JJ	O
for  	for  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
upon  	upon  	 IN	O
further  	further  	 JJ	O
evaluation  	evaluation  	 NN	O
using  	using  	 VBG	O
the  	the  	 DT	O
highly  	highly  	 RB	O
specific  	specific  	 JJ	O
MPA 	MPA 	 NNP	B-NP
.  	.  	 .	O
Of  	Of  	 IN	O
note 	note 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
RIPA-C-positive  	RIPA-C-positive  	 JJ	B-NP
group  	group  	 NN	I-NP
had  	had  	 VBD	O
a  	a  	 DT	O
responder  	responder  	 JJ	B-NP
rate  	rate  	 NN	I-NP
of  	of  	 IN	O
100 	100 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
mean  	mean  	 JJ	O
response  	response  	 NN	O
of  	of  	 IN	O
103.3  	103.3  	 CD	O
days 	days 	 NNS	O
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
RIPA-C-negative  	RIPA-C-negative  	 JJ	B-NP
group  	group  	 NN	I-NP
had  	had  	 VBD	O
a  	a  	 DT	O
responder  	responder  	 JJ	B-NP
rate  	rate  	 NN	I-NP
of  	of  	 IN	O
90 	90 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
mean  	mean  	 JJ	O
response  	response  	 NN	O
of  	of  	 IN	O
89.4  	89.4  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
safety  	safety  	 NN	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
did  	did  	 VBD	O
not  	not  	 RB	O
appear  	appear  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
altered  	altered  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
RIPA-C-positive  	RIPA-C-positive  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
dose  	dose  	 NN	O
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
interval  	interval  	 VBZ	I-NP
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
correction  	correction  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
,  	,  	 ,	O
induction  	induction  	 VBG	B-NP
of  	of  	 IN	O
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
was  	was  	 VBD	O
not  	not  	 RB	O
observed 	observed 	 VBD	O
.  	.  	 .	O
None  	None  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
five  	five  	 CD	O
samples  	samples  	 NNS	O
that  	that  	 WDT	O
initially  	initially  	 RB	O
gave  	gave  	 VBD	O
positive  	positive  	 JJ	B-NP
results  	results  	 NNS	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
RIPA-C  	RIPA-C  	 JJ	B-NP
assay  	assay  	 NN	I-NP
were  	were  	 VBD	O
positive  	positive  	 JJ	O
when  	when  	 WRB	O
further  	further  	 RB	O
evaluated  	evaluated  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
MPA 	MPA 	 NNP	B-NP
.  	.  	 .	O
Clinically 	Clinically 	 NNP	O
,  	,  	 ,	O
RIPA-C-positive  	RIPA-C-positive  	 JJ	B-NP
status  	status  	 NN	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
correlate  	correlate  	 VBN	O
with  	with  	 IN	O
any  	any  	 DT	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
efficacy  	efficacy  	 NN	O
or  	or  	 CC	O
an  	an  	 DT	O
altered  	altered  	 JJ	O
safety  	safety  	 NN	O
profile 	profile 	 NN	O
,  	,  	 ,	O
although  	although  	 IN	O
the  	the  	 DT	O
small  	small  	 JJ	O
numbers  	numbers  	 NNS	O
prevent  	prevent  	 VBP	O
definitive  	definitive  	 JJ	O
conclusions 	conclusions 	 NNS	O
.  	.  	 .	O
These  	These  	 DT	O
data  	data  	 NNS	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
the  	the  	 DT	O
five  	five  	 CD	O
RIPA-C-positive  	RIPA-C-positive  	 JJ	B-NP
samples  	samples  	 NNS	I-NP
represented  	represented  	 VBD	O
false  	false  	 JJ	O
positives 	positives 	 NN	O
.  	.  	 .	O
